July 2022

UROLOGY

UPDATE ON FIRST BIOMARKER-DIRECTED TRIAL OF NON-MUSCLE-INVASIVE BLADDER CANCER

Episode Summary

Erdafitinib (balversa), an oral pan-fibroblast growth factor receptor (FGFR) 1-4 inhibitor, is being used in one of the first biomarker-directed trials of high-risk non-muscle-invasive bladder cancer (NMIBC). The Thor-2 trial (NCT04172675) targets tumors with driver mutations in the FGFR3 gene. This gene is altered in 40% to 70% of early-stage bladder cancers and may be a rare driver mutation in bladder cancer. If successful, Erdafitinib would the first precision therapy for early stage bladder cancer.

​In this podcast episode, lead investigator Joshua J. Meeks, MD, PhD, explains the Thor-2 trial and how it could be a new paradigm in bladder oncology.

Disclosure Statement: Joshua J. Meeks, MD, PhD has received consulting-related fees from Janssen.
Joshua J. Meeks, MD, PhD, the Edward M. Schaeffer, MD, PhD Professor of Urology, associate professor of Urology and of Biochemistry and Molecular Genetics and a member of the Robert H. Lurie Comprehensive Cancer Center at Northwestern Medicine.

Refer a Patient

Northwestern Medicine welcomes the opportunity to partner with you in caring for your patients. ​

You May Also Like